NeuroPace Reports Preliminary 2024 Revenue Above Guidance and Appoints Scott Huennekens to Board

NeuroPace Inc

2024-FY EPS reported -$0.93 revenue$79,906,000

Preliminary unaudited Q4 2024 revenue expected $21.0M-$21.5M (17-19% growth vs Q4 2023), full year $79.4M-$79.9M (21-22% growth), above initial guidance of $73M-$77M.
Cash and short-term investments as of Dec 31, 2024 expected $52.8M; shares outstanding 30,145,039.
Scott Huennekens appointed to Board of Directors effective Jan 6, 2025; granted options for 15,507 shares at $11.93.
NAUTILUS trial one-year follow-up on track for March 2025; data lock and analysis in Q2 2025.
Management to present at J.P. Morgan Healthcare Conference Jan 15 and host Investor Day Jan 28 in NYC.

item 2.02 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Scott Huennekens

Director

NPCE · NeuroPace Inc

Effective: 2025-01-06
Filed: January 8, 2025, 6:59 PM ET

appointed Scott Huennekens as a director to fill the newly created vacancy, effective as of January 6, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Huennekens was appointed as Director at NeuroPace Inc.

Action: appointed
Role: Director

Exact text from the filing

appointed Scott Huennekens as a director to fill the newly created vacancy, effective as of January 6, 2025.

View on SEC.gov

NeuroPace Inc filing history →

Source: SEC EDGAR

accession 0001193125-25-003547

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.